TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00608595

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Not noted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: not noted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: not noted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
Study: NCT02501447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided audio-visual relaxation
Study: NCT04049357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camera Capsule Endoscopy/ PillCam
Description: Camera Capsule Endoscopy in screening
Study: NCT03693300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
Study: NCT02598804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 educational workshop

Intervention type: OTHER
Group type: OTHER
Intervention: written information booklet
Study: NCT02074644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic Arterial Embolization
Description: The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
Study: NCT02173223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor
Study: NCT00686283

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEP intervention
Description: This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
Study: NCT00150709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use
Study: NCT01261806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up
Description: Enhances nurturance, following the lead, and calming behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Attention control: Enhances parents understanding of developmental milestones
Study: NCT02141802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doubling standing time
Description: Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
Study: NCT04004559

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.
Study: NCT01758666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate,Calcium folinate
Study: NCT04434820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External negative pressure dressing system (Yuwell 7E-A portable suction unit)
Description: A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
Study: NCT01446601

Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Description: The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
Study: NCT01130467

Intervention type: DRUG
Intervention: methylphenidate
Description: IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.

Intervention type: DRUG
Intervention: Atomoxetine
Description: Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).

Intervention type: DRUG
Intervention: Atomoxetine
Description: Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
Study: NCT00608595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: not noted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: not noted
Study: NCT04332848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET
Description: Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGT
Description: Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Study: NCT01800526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Oral and Intravenous administration of NAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Oral and Intravenous administration of NAC
Study: NCT03438539

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Normative Feedback
Description: Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
Study: NCT01130467

Intervention type: BEHAVIORAL
Intervention: behavioral modification
Description: Parenting and teaching skill education

Intervention type: BEHAVIORAL
Intervention: behavioral modification
Description: Parenting and teaching skill education
Study: NCT01551056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 2 separate times during a 14 day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT00131144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate in Microspheres 20 mg
Study: NCT01446601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Description: The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
Study: NCT00153894

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
Study: NCT00131144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate in Microspheres

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02550197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
Description: 0.5 mL, Intramuscular
Study: NCT00795054

Intervention type: OTHER
Intervention: Household financial data collection
Description: Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
Study: NCT02345018

Intervention type: PROCEDURE
Intervention: Mechano-chemical ablation
Description: Treatment with mechano-chemical ablation
Study: NCT01891279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elemental formula Elecare®
Description: Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partially hydrolyzed formula
Description: Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
Study: NCT02882347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Study: NCT02345018

Intervention type: PROCEDURE
Intervention: Mechano-chemical ablation
Description: Treatment with mechano-chemical ablation

Intervention type: PROCEDURE
Intervention: Mechano-chemical ablation
Description: Treatment with mechano-chemical ablation
Study: NCT00153894

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Cardiovascular training at home for 30 minutes three times per week for 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
Study: NCT03766802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable watch training group.
Description: 3 orientation session Watch notifies 3/week for exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application training group.
Description: 3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Supervised exercise training group
Description: 3/week training supervised by a physical therapist
Study: NCT02428452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social ABCs parent-mediated intervention program
Description: The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
Study: NCT03722784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invigor A (test)
Description: silicone hydrogel lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invigor B (control)
Description: silicone hydrogel lens
Study: NCT02038218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Demethyl-4-cholestryloxycarbonylpenclomedine
Description: This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance.
Study: NCT00634452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1401
Description: IV weekly for 4 weeks
Study: NCT00773084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
Description: Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
Study: NCT00724763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: to Liv 3 and PE 9.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham needle treatment
Description: needle not in meridian area
Study: NCT04015804

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical database
Description: Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
Study: NCT02566863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
Study: NCT04128358

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological assay for blood born viral hepatitis
Description: Qualitative PCR for patients with hepatitis C antibody positive

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serological assay for blood born viral hepatitis
Description: Qualitative PCR for patients with hepatitis C antibody positive

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serological assay for blood born viral hepatitis
Description: Qualitative PCR for patients with hepatitis C antibody positive

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative microbiological test for HCV
Description: Quantitative PCR in those with proven HCV infection

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative microbiological test for HCV
Description: Quantitative PCR in those with proven HCV infection

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative microbiological test for HCV
Description: Quantitative PCR in those with proven HCV infection
Study: NCT02389777

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266 immediate
Description: ST266 will be applied immediately to the UV light burn wound topically by spray twice per day

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266 delayed
Description: ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
Study: NCT04558788

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry on intestinal biopsies
Description: Immunohistochemistry will be performed on human intestinal biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry on intestinal biopsies
Description: Immunohistochemistry will be performed on human intestinal biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry on intestinal biopsies
Description: Immunohistochemistry will be performed on human intestinal biopsies
Study: NCT03216317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Isometric handgrip training consisting of four series
Study: NCT05534204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silk suture
Description: Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polyester suture
Description: Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.
Study: NCT03204968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve stimulation
Description: transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
Study: NCT02355197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ascorbic acid
Description: 1 gram L-ascorbic acid (vitamin C .....) per day from the time of diagnosis until the time of delivery
Study: NCT00150709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use
Study: NCT01985789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Study: NCT05253664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Woman-Centered Care Group
Description: Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
Study: NCT00186186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakote ER
Description: Depakote ER
Study: NCT03319680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Citrate dialysate
Description: Compare the effect of citrate dialysate with acetate dialysate
Study: NCT00382681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 107027 Multi-Purpose Disinfecting Solution
Description: Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution No Rub Formula
Description: Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
Study: NCT02349503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-77860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-77860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-77860
Study: NCT05863481

Intervention type: PROCEDURE
Intervention: Laparoscopic cerclage placement
Description: The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)